UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Oct

    31

    NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

    Aug

    17

    UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

    Dec

    04

    Spencer’s Story: What to Know About Seizure Clusters

    At just one day old, Spencer, born in Greenville, South Carolina, had his first seizure, a sudden, uncontrolled electrical disturbance in the brain that usually causes a change in behavior.1,2

    Nov

    25

    Press Release: UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

    • NAYZILAM will be available in retail pharmacies on December 2, 2019
    • Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*

    Oct

    21

    Disease Spotlight: Seizure Clusters

    At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.